Stock 300529 JAFRON BIOMEDICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Jafron Biomedical Co.,Ltd.

Equities

300529

CNE100002995

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 29/04/2024 BST 		5-day change 1st Jan Change
27.54 CNY +1.62% Intraday chart for Jafron Biomedical Co.,Ltd. +20.79% +23.89%
04-26 Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023 CI
04-25 Jafron Biomedical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Analyst opinion has improved significantly over the past four months.

Weaknesses

  • With a 2024 P/E ratio at 27.54 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
JAFRON BIOMEDICAL CO.,LTD. Stock Jafron Biomedical Co.,Ltd.
+23.89% 2.95B
D+
ABBOTT LABORATORIES Stock Abbott Laboratories
-3.43% 184B
C+
MEDTRONIC PLC Stock Medtronic plc
-1.81% 107B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.15% 67.52B
A
DEXCOM, INC. Stock DexCom, Inc.
+1.43% 50.06B
B-
CENCORA, INC. Stock Cencora, Inc.
+11.60% 45.67B
B-
HOYA CORPORATION Stock Hoya Corporation
+3.40% 41B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+3.03% 26.73B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+3.21% 26.47B
A-
TERUMO CORPORATION Stock Terumo Corporation
+15.23% 25.05B
A-
Investor Rating
Trading Rating
-
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 300529 Stock
  4. Ratings Jafron Biomedical Co.,Ltd.